News NICE relents and backs Kisqali for wide use in breast cancer Novartis' breast cancer therapy Kisqali has been cleared for NHS use in early breast cancer, an indication driving blockbuster sales of the drug.
News First malaria drug for newborns and young infants cleared A new formulation of Novartis' antimalarial Coartem has become the first medicine to be approved for use in very young children.
News Novartis drug flunks phase 3 test in giant cell arteritis Novartis hopes of bringing Cosentyx to patients with giant cell arteritis seem to be over after the drug missed all the endpoints in a phase 3 trial.
News ASCO 25: Roche places Itovebi marker in breast cancer Roche's Itovebi has become the first PI3K inhibitor to extend survival in HR-positive, HER2-negative breast cancer with a PIK3CA mutation.
News PTC's Huntington study was positive. Why did its stock fall? In a potentially pivotal trial, PTC Therapeutics' therapy for Huntington's disease met its primary endpoint, but there are questions about the data.
News Novartis grabs kidney drug developer Regulus in $1.7bn deal Novartis has grown in renal diseases once again with a $1.7bn deal to buy Regulus and its autosomal dominant polycystic kidney disease (ADPKD) drug.
News EC clears first treatment for high-risk smouldering multiple... Johnson & Johnson’s Janssen-Cilag has secured European Commission approval for a new indication of its subcutaneous formulation of DARZALEX
Market Access The value of a partner, globally and locally A new podcast looks at recent trends related to drug approvals, as well as challenges and opportunities both small and large pharma companies face